title: Comment on "A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia" by Kinon et al.
authors.forename: Philip
authors.initials: P
authors.lastname: Seeman
mesh_terms: D000596:Amino Acids / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D012559:Schizophrenia / Q000188:drug therapy*
chemical_list: D000596:Amino Acids; D014150:Antipsychotic Agents; D001569:Benzodiazepines